Posts

Posted on

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of ZAGG Inc Buyout

WILMINGTON, Del., Dec. 11, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating ZAGG Inc (“ZAGG”) (NASDAQ GS: ZAGG) regarding possible breaches of fiduciary duties and other violations of law related to ZAGG’s agreement to be acquired by a buyer group led by Evercel, Inc. Under the terms of the agreement, ZAGG’s shareholders will receive $4.50 in cash per share and an additional contingent amount of up to $0.25 in cash per share if certain conditions are met.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-zagg-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com



Posted on

Kraig Biocraft Laboratories Secures Bridge Funding and Files to Become Fully Reporting Company

ANN ARBOR, Mich., Dec. 11, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $950,000 in bridge financing and simultaneously filed with the SEC to become a mandatory, fully reporting company. Today the Company filed a Form 8-A to become fully reporting issuer. This financing will also make a significant contribution to that effort.

“While being a voluntary filer, Kraig has been committed to meeting all SEC filing and reporting standards. Our election to now formalize these reporting responsibilities is evidence of our commitment to full operational transparency and growth,” said CEO and Founder, Kim Thompson. “The bridge financing will be used to continue scaling up our recombinant spider silk production and for other purposes related to the near term implementation of our business plan.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
[email protected]



Posted on

Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline

Ziopharm Recommends Shareholders Return the


GREEN


Consent Revocation Card

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company’s GREEN Consent Revocation Card.

The statement is as follows:

“We have been informed that WaterMill has requested to delay the voting deadline until December 15, a clear sign that it does not appear to have the level of shareholder support for its proposals it claimed to have. As has been the case since this process commenced in mid-October, Ziopharm’s Board and management team remain fully committed to acting in the best interest of shareholders and have relayed the Company’s willingness to reach an amicable resolution with WaterMill. It is our preference to resolve this matter amicably so we can continue to focus on our important progress toward developing therapies that could treat the millions of people globally diagnosed with a solid tumor each year.”

Information related to the Consent Solicitation can be found at www.ZiopharmForward.com.

About Ziopharm Oncology, Inc.

Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the business strategy, plans and objectives of Ziopharm management and expectations as to and beliefs about the Consent Solicitation initiated by WaterMill. Forward-looking statements include all statements that are not historical facts, and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include, among others, the impact and results of the Consent Solicitation and other activities by WaterMill and/or other investors, the risks and uncertainties disclosed in Ziopharm’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as well as discussions of potential risks, uncertainties and other important factors in any subsequent filings by Ziopharm with the Securities and Exchange Commission (the “SEC”). All information in this press release is as of the date hereof, and Ziopharm undertakes no duty to update the information, except as required by law.

Important Additional Information and Where to Find It

Ziopharm has filed a definitive consent revocation statement (the “Consent Revocation Statement”) together with a GREEN consent revocation card with the SEC in connection with the Consent Solicitation. SHAREHOLDERS ARE URGED TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ZIOPHARM FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the Consent Revocation Statement (including the GREEN consent revocation card), any amendments or supplements thereto and any other documents that Ziopharm files with the SEC from the SEC’s website (http://www.sec.gov) or from Ziopharm’s website (www.ziopharm.com) by clicking on “Investors” and then “SEC Filings.”

Investor Relations Contacts:

Adam D. Levy, PhD, MBA
EVP, Investor Relations and Corporate Communications
(508) 552-9255
[email protected]

Michael Verrechia
Morrow Sodali
(212) 300-2476
[email protected]

Media Relations Contacts:

Chris Kittredge, Andrew Cole and Zachary Tramonti
Sard Verbinnen & Co.
[email protected]

 



Posted on

SHAREHOLDER ALERT: WeissLaw LLP Reminds ROCH, TOTA, and DMYD Shareholders About Its Ongoing Investigations

PR Newswire

NEW YORK, Dec. 11, 2020 /PRNewswire/ —


If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:


Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

Roth CH Acquisition I Co. (NASDAQ: ROCH)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Roth CH Acquisition I Co. (NASDAQ: ROCH) in connection with the company’s proposed merger with privately-held PureCycle Technologies LLC (“PureCycle”).  Under the terms of the agreement, ROCH will acquire PureCycle through a reverse merger that will result in PureCycle becoming a public company traded on the NASDAQ Capital Market.  If you own ROCH shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/roch/

Tottenham Acquisition I Limited
(NASDAQ: TOTA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tottenham Acquisition I Limited (NASDAQ: TOTA) in connection with the company’s proposed merger with privately-held clinical-stage biopharmaceutical company, Clene Nanomedicine, Inc. (“Clene”).  Under the terms of the agreement, TOTA will acquire Clene through a reverse merger that will result in Clene becoming a public company.  If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/tottenham-acquisition-i-limited/

dMY Technology Group, Inc. II (NYSE: DMYD)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of dMY Technology Group, Inc. II (NYSE: DMYD) in connection with the company’s proposed merger with Genius Sports Group Limited (“GSG”).  Under the terms of the agreement, DMYD will acquire GSG through a reverse merger that will result in GSG becoming a public company.  If you own DMYD shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/dmyd/

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-roch-tota-and-dmyd-shareholders-about-its-ongoing-investigations-301191459.html

SOURCE WeissLaw LLP

Posted on

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Qiwi plc – QIWI

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Qiwi plc – QIWI

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Qiwi plc (NASDAQ: QIWI) between March 28, 2019 and December 9, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Qiwi investors under the federal securities laws.

To join the Qiwi class action, go http://www.rosenlegal.com/cases-register-2005.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Qiwi’s internal controls related to reporting and record-keeping were ineffective; (2) consequently, the Central Bank of Russia would impose a monetary fine upon the Company and impose restrictions upon the Company’s ability to make payments to foreign merchants and transfer money to pre-paid cards; and (3) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-2005.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm – BIIB

PR Newswire

NEW YORK, Dec. 11, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the “Class Period”) of the important January 12, 2021 lead plaintiff deadline in the securities class action commenced by the Firm. The lawsuit seeks to recover damages for Biogen investors under the federal securities laws.

To join the Biogen class action, go to http://www.rosenlegal.com/cases-register-1981.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants’ statements about Biogen’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1981.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-globally-recognized-law-firm-reminds-biogen-inc-investors-of-important-january-12-deadline-in-securities-class-action-first-filed-by-the-firm-encourages-investors-with-losses-in-excess-of-1-million-to-contact-the-firm-301191497.html

SOURCE Rosen Law Firm, P.A.

Posted on

BlackBerry Prevails Against MobileIron’s Baseless Extortion Claims

PR Newswire

WATERLOO, ON, Dec. 11, 2020 /PRNewswire/ — BlackBerry Limited (NYSE: BB; TSX: BB) today announced that earlier this week, a California federal court approved a stipulation submitted by MobileIron dismissing with prejudice claims MobileIron filed earlier this year alleging that BlackBerry attempted to “extort” MobileIron into entering a patent licensing agreement. As a result, MobileIron will have to pay BlackBerry’s costs and attorney’s fees in defending against those claims. 

In its complaint filed earlier this year, MobileIron claimed that BlackBerry attempted “civil extortion” by sending MobileIron notices of patent infringement.  But as BlackBerry maintained throughout the suit, BlackBerry’s efforts to enforce its patent rights were at all times proper, and MobileIron’s claims to the contrary were both “abusive” and “meritless.” The dismissal of MobileIron’s claims vindicates BlackBerry’s position and the propriety of BlackBerry’s licensing practices.

“BlackBerry is a pioneer in mobile security and enterprise software and has always stood behind its technologies and licensing practices,” said Steve Rai, Chief Financial Officer, BlackBerry. “We are gratified that these meritless claims have been definitively put to rest and will continue to vigorously defend BlackBerry’s position. We appreciate the change in direction that Ivanti, MobileIron’s new owner, has taken with respect to this suit and look forward to working with them to reconcile the remaining open items.”

BlackBerry’s portfolio consists of approximately 38,000 worldwide patents and applications covering a wide array of technologies including wireless communications, networking infrastructure, acoustics, messaging, enterprise software, operating systems, virtualization and cybersecurity.

About BlackBerry
BlackBerry (NYSE: BB; TSX: BB) provides intelligent security software and services to enterprises and governments around the world. The company secures more than 500M endpoints including over 175M cars on the road today.  Based in Waterloo, Ontario, the company leverages AI and machine learning to deliver innovative solutions in the areas of cybersecurity, safety and data privacy solutions, and is a leader in the areas of endpoint security management, encryption, and embedded systems.  BlackBerry’s vision is clear – to secure a connected future you can trust.

BlackBerry. Intelligent Security. Everywhere. 
For more information, visit BlackBerry.com and follow @BlackBerry.  

Trademarks, including but not limited to BLACKBERRY, EMBLEM Design and QNX are the trademarks or registered trademarks of BlackBerry Limited, its subsidiaries and/or affiliates, used under license, and the exclusive rights to such trademarks are expressly reserved. All other trademarks are the property of their respective owners. BlackBerry is not responsible for any third-party products or services.

Media Contact:
BlackBerry Media Relations
+1 (519) 597-7273
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/blackberry-prevails-against-mobileirons-baseless-extortion-claims-301191498.html

SOURCE BlackBerry Limited

Posted on

Voya Announces Investor Call to Discuss the Following Board Approved Changes to the Principal Investment Strategies and the Primary Benchmark for Voya Global Advantage and Premium Opportunity Fund

Voya Announces Investor Call to Discuss the Following Board Approved Changes to the Principal Investment Strategies and the Primary Benchmark for Voya Global Advantage and Premium Opportunity Fund

NEW YORK–(BUSINESS WIRE)–
The Board of Trustees (“the Board”) of Voya Global Advantage and Premium Opportunity Fund (the “Fund”) (NYSE: IGA) has approved changes to the Fund’s principal investment strategies and primary benchmark (from MSCI World IndexSM to the MSCI World Value IndexSM). The proposed changes to the Fund’s principal investment strategies better describe the security selection process resulting from the change in benchmark. Each of the foregoing changes will be effective on or about December 31, 2020.

Information regarding the investor call details can be found later in this press release.

Investment Strategies

The Fund will maintain its current, primary investment objective of providing a high level of income, and its secondary objective of capital appreciation. The Fund will continue to utilize an integrated option strategy. A description of the revised portions of the Fund’s equity investment strategies are included below:

The Fund seeks to invest in a portfolio of equity securities included in the MSCI World Value IndexSM (the “Index”) and will select securities based upon quantitative analysis. The Sub-Adviser creates a target universe that consists of dividend paying securities by screening for companies that exhibit stable dividend yields within each industry sector. Once the Sub-Adviser creates this target universe, the Sub-Adviser seeks to identify the most attractive securities within various geographic regions and sectors by ranking each security relative to other securities within its region or sector, as applicable, using proprietary fundamental sector-specific models. The Sub-Adviser then uses optimization techniques to seek to achieve the portfolio’s target dividend yield, which is expected to be higher than the Index in aggregate, manage target beta, determine active weights, and neutralize region and sector exposures in order to create a portfolio that the Sub-Adviser believes will provide the potential for maximum total return consistent with maintaining lower volatility than the Index. Under certain market conditions, the Fund will likely earn a lower level of total return than it would in the absence of its strategy of maintaining a relatively lower level of volatility.

Portfolio Management

The Fund is managed by Paul Zemsky, CFA, Vincent Costa, CFA, Peg DiOrio, CFA, and Steve Wetter, Voya Investment Management Co. LLC (“VIM”) — the Sub-Adviser.

Upcoming Webcast

Voya Investment Management, the asset management business of Voya Financial, Inc., will host a webcast for Voya Global Advantage and Premium Opportunity Fund on Thursday, December 17, 2020 from 5:00 p.m. – 5:30 p.m. ET.

Hosted by Vinnie Costa, Portfolio Manager, the conference call will provide:

  • A review of the strategy and benchmark changes
  • A review of the markets that the funds invest in

To register for the webcast, please visit www.voyainvestments.com/CEF. The investment team will also address investor questions. To submit questions in advance, please email [email protected] by Wednesday, December 16th.

A replay will be made available on our website for those who cannot attend.

About Voya Investment Management

A leading, active asset management firm, Voya Investment Management manages, as of September 30, 2020, over $238 billion for affiliated and external institutions as well as individual investors. With more than 40 years of history in asset management, Voya Investment Management has the experience and resources to provide clients with investment solutions with an emphasis on equities, fixed income, and multi-asset strategies and solutions. Voya Investment Management was named in 2015, 2016, 2017, 2018 and 2019 as a “Best Places to Work” by Pensions and Investments magazine. For more information, visit voyainvestments.com. Follow Voya Investment Management on Twitter @VoyaInvestments.

SHAREHOLDER INQUIRIES: Shareholder Services at (800) 992-0180; voyainvestments.com

CONTACT: Kris Kagel, (212) 309-6568

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo
Posted on

Voya Announces Investor Call to Discuss the Following Board Approved Changes to the Principal Investment Strategies and the Primary Benchmark for Voya Global Equity Dividend and Premium Opportunity Fund

Voya Announces Investor Call to Discuss the Following Board Approved Changes to the Principal Investment Strategies and the Primary Benchmark for Voya Global Equity Dividend and Premium Opportunity Fund

NEW YORK–(BUSINESS WIRE)–
The Board of Trustees (“the Board”) of Voya Global Equity Dividend and Premium Opportunity Fund (the “Fund”) (NYSE: IGD) has approved changes to the Fund’s principal investment strategies and primary benchmark (from MSCI World IndexSM to the MSCI World Value IndexSM). The proposed changes to the Fund’s principal investment strategies better describe the security selection process resulting from the change in benchmark. Each of the foregoing changes will be effective on or about December 31, 2020.

Information regarding the investor call details can be found later in this press release.

Investment Strategies

The Fund will maintain its current, primary investment objective of providing a high level of income, and its secondary objective of capital appreciation. The Fund will continue to utilize an integrated option strategy. A description of the revised portions of the Fund’s equity investment strategies are included below:

The Fund seeks to invest in a portfolio of equity securities included in the MSCI World Value IndexSM (the “Index”) and will select securities based upon quantitative analysis. The Sub-Adviser creates a target universe that consists of dividend paying securities by screening for companies that exhibit stable dividend yields within each industry sector. Once the Sub-Adviser creates this target universe, the Sub-Adviser seeks to identify the most attractive securities within various geographic regions and sectors by ranking each security relative to other securities within its region or sector, as applicable, using proprietary fundamental sector-specific models. The Sub-Adviser then uses optimization techniques to seek to achieve the portfolio’s target dividend yield, which is expected to be higher than the Index in aggregate, manage target beta, determine active weights, and neutralize region and sector exposures in order to create a portfolio that the Sub-Adviser believes will provide the potential for maximum total return consistent with maintaining lower volatility than the Index. Under certain market conditions, the Fund will likely earn a lower level of total return than it would in the absence of its strategy of maintaining a relatively lower level of volatility.

Portfolio Management

The Fund is managed by Paul Zemsky, CFA, Vincent Costa, CFA, Peg DiOrio, CFA, and Steve Wetter, Voya Investment Management Co. LLC (“VIM”) — the Sub-Adviser.

Upcoming Webcast

Voya Investment Management, the asset management business of Voya Financial, Inc., will host a webcast for Voya Global Equity Dividend and Premium Opportunity Fund on Thursday, December 17, 2020 from 5:00 p.m. – 5:30 p.m. ET.

Hosted by Vinnie Costa, Portfolio Manager, the conference call will provide:

  • A review of the strategy and benchmark changes
  • A review of the markets that the funds invest in

To register for the webcast, please visit www.voyainvestments.com/CEF. The investment team will also address investor questions. To submit questions in advance, please email [email protected] by Wednesday, December 16th.

A replay will be made available on our website for those who cannot attend.

About Voya Investment Management

A leading, active asset management firm, Voya Investment Management manages, as of September 30, 2020, over $238 billion for affiliated and external institutions as well as individual investors. With more than 40 years of history in asset management, Voya Investment Management has the experience and resources to provide clients with investment solutions with an emphasis on equities, fixed income, and multi-asset strategies and solutions. Voya Investment Management was named in 2015, 2016, 2017, 2018 and 2019 as a “Best Places to Work” by Pensions and Investments magazine. For more information, visit voyainvestments.com. Follow Voya Investment Management on Twitter @VoyaInvestments.

SHAREHOLDER INQUIRIES: Shareholder Services at (800) 992-0180; voyainvestments.com

CONTACT: Kris Kagel, (212) 309-6568

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo
Posted on

Lefteris Acquisition Corp. Announces the Separate Trading of its Shares of Class A Common Stock and Redeemable Warrants Commencing December 15, 2020

PR Newswire

NEW YORK, Dec. 11, 2020 /PRNewswire/ — Lefteris Acquisition Corp. (Nasdaq: LFTRU) (the “Company”) announced that, commencing December 15, 2020, holders of the units sold in the Company’s initial public offering of 20,709,894 units, may elect to separately trade the shares of Class A common stock and redeemable warrants included in the units. Those units not separated will continue to trade on the Nasdaq Stock Market (“Nasdaq”) under the symbol “LFTRU,” and the shares of Class A common stock and redeemable warrants that are separated will trade on Nasdaq under the symbols “LFTR” and “LFTRW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A common stock and redeemable warrants.

The units were initially offered by the Company in an underwritten offering. Morgan Stanley & Co. LLC acted as book-running manager of the offering. Registration statements relating to the units and the underlying securities became effective on October 20, 2020.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering was made only by means of a prospectus, copies of which may be obtained for free from the SEC website at www.sec.gov or by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, Email: [email protected].

About Lefteris Acquisition Corp.

Lefteris Acquisition Corp. is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination with a company in any business, industry, sector or geographical location, it intends to focus its search on the financial technology sector.

Forward-Looking Statements

This press release may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus relating to the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact


Jon Isaacson


[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/lefteris-acquisition-corp-announces-the-separate-trading-of-its-shares-of-class-a-common-stock-and-redeemable-warrants-commencing-december-15-2020-301191489.html

SOURCE Lefteris Acquisition Corp.